RED: NICE TA416 for treating locally advanced or metastatic EGFR T790M mutation positive non-small cell lung cancer. (Decision date - November 2016)
RED: NICE TA653 for treating EGFR T790M mutation-positive locally advanced or metastatic NSCLC. (Decision date - November 2020)
RED: NICE TA654 for untreated EGFR mutation-positive NSCLC. (Replaces TA621). (Decision date - November 2020)
RED: NICE TA761 - Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection. (Decision date - February 2022)
DO NOT PRESCRIBE (DNP): NICE TA621 - for untreated EGFR mutation-positive non-small-cell lung cancer. (Decision date - February 2020)